The European Medicines Agency (EMEA) has announced the marketing authorisation of MycamineŽ, Astellas Pharma Europe’s treatment for invasive candidiasis, oesophageal candidiasis and prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation. MycamineŽ will initially be available in the U.K and across the European market shortly after this.

More: continued here

This entry was posted on Thursday, May 15th, 2008 at 8:05 pm and is filed under Infectious Diseases / Bacteria / Viruses. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.